We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
PerkinElmer, Inc. is slated to release first-quarter 2021 results on May 4, after the closing bell. In the last reported quarter, the company delivered an earnings surprise of 9.7%. Further, its earnings beat estimates in each of the trailing four quarters, the average surprise being 42.1%.
Q1 Estimates
Currently, the Zacks Consensus Estimate for first-quarter revenues is pegged at $1.19 billion, suggesting growth of 82.9% from the year-ago reported figure. The consensus mark for earnings stands at $3.03 per share, indicating a significant improvement from the prior-year quarter.
Diagnostics Revenues: A Key Catalyst
PerkinElmer's Diagnostics segment is likely to have favored the to-be-reported quarter’s performance. Strength in immunodiagnostics and applied genomics business might get reflected in the segment’s first-quarter revenues.
Further, the continued rise in infectious and autoimmune diseases, especially in emerging markets, may have benefited the segment.
In March, the company introduced two Research Use Only (RUO) solutions — PKamp VariantDetect SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX Variant-Seq SARS-CoV-2 Kit — to detect genomic mutations reported in connection to SARS-CoV-2 variants. Notably, laboratories can utilize these assays through nucleic acid extracted from samples that tested positive earlier.
In the same month, Horizon Discovery (a PerkinElmer company) expanded its gene editing and modulation portfolio to include a new family of CRISPR modulation (CRISPRmod) reagents for CRISPR interference (CRISPRi).
In January, PerkinElmer received Emergency Use Authorization (EUA) from the FDA for its New Coronavirus Nucleic Acid Detection Kit. The New Coronavirus Nucleic Acid Detection Kit is a real-time RT-PCR test intended to test individuals without symptoms or other reasons to detect COVID-19 infection. With this approval, clinical laboratories that are certified under Clinical Laboratory Improvement Amendments (CLIA) can now start utilizing this kit to test both symptomatic and asymptomatic individuals.
In November 2020, the company announced that its SARS-CoV-2 Real-time RT-PCR (reverse transcription-polymerase chain reaction) Assay received CE-IVD marking for the utilization of saliva as specimen type and the choice to combine up to five specimens from suspected COVID-19 infected or asymptomatic individuals.
These developments are likely to have positively impacted the company’s Diagnostics segment in the first quarter. This, in turn, might get reflected in the company’s to-be-reported quarter’s results.
Other Factors to Note
PerkinElmer is likely to have witnessed solid international growth in the to-be-reported quarter. Improved momentum in Europe and consistent growth trend in the United States might have contributed to the first-quarter performance.
Additionally, the company’s Discovery product portfolio may have witnessed strong demand courtesy of sustained robust performance by life sciences.
Productivity initiatives, volume leverage and strict cost control measures are likely to have contributed to the company’s first-quarter gross and operating margins. New product introductions might have improved product mix and thereby gross margin.
However, PerkinElmer’s exposure to the international markets increases the risk of foreign exchange volatility. The fluctuations in currency exchange rates might have weighed on the company’s international sales in the to-be-reported quarter.
Here’s What the Quantitative Model Suggests
Our proven model conclusively predicts an earnings beat for PerkinElmer this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.
Earnings ESP: PerkinElmer has an Earnings ESP of +1.32%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: PerkinElmer sports a Zacks Rank #3.
Other Stocks Worth a Look
Here are some other medical stocks worth considering as these too have the right combination of elements to post an earnings beat this quarter.
AmerisourceBergen Corporation has an Earnings ESP of +0.23% and a Zacks Rank of 3.
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) has an Earnings ESP of +1.92% and a Zacks Rank of 3.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Image: Bigstock
PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards?
PerkinElmer, Inc. is slated to release first-quarter 2021 results on May 4, after the closing bell. In the last reported quarter, the company delivered an earnings surprise of 9.7%. Further, its earnings beat estimates in each of the trailing four quarters, the average surprise being 42.1%.
Q1 Estimates
Currently, the Zacks Consensus Estimate for first-quarter revenues is pegged at $1.19 billion, suggesting growth of 82.9% from the year-ago reported figure. The consensus mark for earnings stands at $3.03 per share, indicating a significant improvement from the prior-year quarter.
Diagnostics Revenues: A Key Catalyst
PerkinElmer's Diagnostics segment is likely to have favored the to-be-reported quarter’s performance. Strength in immunodiagnostics and applied genomics business might get reflected in the segment’s first-quarter revenues.
Further, the continued rise in infectious and autoimmune diseases, especially in emerging markets, may have benefited the segment.
In March, the company introduced two Research Use Only (RUO) solutions — PKamp VariantDetect SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX Variant-Seq SARS-CoV-2 Kit — to detect genomic mutations reported in connection to SARS-CoV-2 variants. Notably, laboratories can utilize these assays through nucleic acid extracted from samples that tested positive earlier.
PerkinElmer, Inc. Price and EPS Surprise
PerkinElmer, Inc. price-eps-surprise | PerkinElmer, Inc. Quote
In the same month, Horizon Discovery (a PerkinElmer company) expanded its gene editing and modulation portfolio to include a new family of CRISPR modulation (CRISPRmod) reagents for CRISPR interference (CRISPRi).
In January, PerkinElmer received Emergency Use Authorization (EUA) from the FDA for its New Coronavirus Nucleic Acid Detection Kit. The New Coronavirus Nucleic Acid Detection Kit is a real-time RT-PCR test intended to test individuals without symptoms or other reasons to detect COVID-19 infection. With this approval, clinical laboratories that are certified under Clinical Laboratory Improvement Amendments (CLIA) can now start utilizing this kit to test both symptomatic and asymptomatic individuals.
In November 2020, the company announced that its SARS-CoV-2 Real-time RT-PCR (reverse transcription-polymerase chain reaction) Assay received CE-IVD marking for the utilization of saliva as specimen type and the choice to combine up to five specimens from suspected COVID-19 infected or asymptomatic individuals.
These developments are likely to have positively impacted the company’s Diagnostics segment in the first quarter. This, in turn, might get reflected in the company’s to-be-reported quarter’s results.
Other Factors to Note
PerkinElmer is likely to have witnessed solid international growth in the to-be-reported quarter. Improved momentum in Europe and consistent growth trend in the United States might have contributed to the first-quarter performance.
Additionally, the company’s Discovery product portfolio may have witnessed strong demand courtesy of sustained robust performance by life sciences.
Productivity initiatives, volume leverage and strict cost control measures are likely to have contributed to the company’s first-quarter gross and operating margins. New product introductions might have improved product mix and thereby gross margin.
However, PerkinElmer’s exposure to the international markets increases the risk of foreign exchange volatility. The fluctuations in currency exchange rates might have weighed on the company’s international sales in the to-be-reported quarter.
Here’s What the Quantitative Model Suggests
Our proven model conclusively predicts an earnings beat for PerkinElmer this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.
Earnings ESP: PerkinElmer has an Earnings ESP of +1.32%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: PerkinElmer sports a Zacks Rank #3.
Other Stocks Worth a Look
Here are some other medical stocks worth considering as these too have the right combination of elements to post an earnings beat this quarter.
Thermo Fisher Scientific Inc. (TMO - Free Report) has an Earnings ESP of +0.25% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.
AmerisourceBergen Corporation has an Earnings ESP of +0.23% and a Zacks Rank of 3.
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) has an Earnings ESP of +1.92% and a Zacks Rank of 3.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Today, Download Marijuana Moneymakers FREE >>